Show simple item record

dc.contributor.authorO'Brien, M
dc.contributor.authorGaafar, R
dc.contributor.authorHasan, B
dc.contributor.authorMenis, J
dc.contributor.authorCufer, T
dc.contributor.authorPopat, S
dc.contributor.authorWoll, P
dc.contributor.authorSurmont, V
dc.contributor.authorGeorgoulias, V
dc.contributor.authorMontes, A
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorHennig, I
dc.contributor.authorSchmid-Bindert, G
dc.contributor.authorBaas, P
dc.date.accessioned2015-07-22T14:05:20Zen
dc.date.available2015-07-22T14:05:20Zen
dc.date.issued2015-08en
dc.identifier.citationMaintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). 2015, 51 (12):1511-28 Eur. J. Canceren
dc.identifier.issn1879-0852en
dc.identifier.pmid26074395en
dc.identifier.doi10.1016/j.ejca.2015.04.026en
dc.identifier.urihttp://hdl.handle.net/10541/560897en
dc.description.abstractSwitch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.titleMaintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).en
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital, London and Sutton, United Kingdom.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractSwitch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC.


Files in this item

This item appears in the following Collection(s)

Show simple item record